

American Cancer Society, Inc.

**2022**

**Board of Directors**



# The American Cancer Society

## 2022 Board of Directors

The American Cancer Society is one of the largest and oldest voluntary health organizations in the world. Established in 1913 by a small group of physicians and businessmen, ACS has been governed by volunteers since its inception.

The Board of Directors is composed of five officers and a range of 12 to 18 at-large directors. The Board sets the vision and mission for the organization and establishes strategic direction and broad policies to enable the organization to fulfill its charitable purposes. The ACS Board of Directors is committed to governing with excellence as guided by national standards and industry best practices.

### **Board Committees:**

- Audit Committee
- Compensation Committee
- Diversity, Equity, and Inclusion Committee
- Finance Committee
- Governance Committee
- Mission Outcomes Committee
- Revenue and Marketing Committee

# American Cancer Society Board of Directors 2022

## Officers

<u>Name</u>	<u>Position</u>	<u>Term End</u>
Michael T. Marquardt	Chair	December 31, 2022
Brian A. Marlow, CFA	Vice Chair	December 31, 2022
Mark A. Goldberg, MD	Board Scientific Officer	December 31, 2022
Katie A. Eccles, Esq.	Secretary/Treasurer	December 31, 2022
John Alfonso, CPA, CGMA	Immediate Past Chair	December 31, 2022

## Directors

<u>Name</u>	<u>Term End</u>
Bruce N. Barron	December 31, 2023
Monica M. Bertagnolli, MD, FASCO	December 31, 2022
Jennifer R. Crozier	December 31, 2023
Asif Dhar, MD, MBA	December 31, 2023
Wayne A. I. Frederick, MD, MBA, FACS	December 31, 2023
Kathleen Gallagher, MSN	December 31, 2023
Carmen E. Guerra, MD, MSCE, FACP	December 31, 2023
Laura Hertz	December 31, 2022
Amit Kumar, PhD	December 31, 2022
Othman Laraki, MS, MBA	December 31, 2023
Michelle M. Le Beau, PhD	December 31, 2022
Connie Lindsey	December 31, 2023
Edison T. Liu, MD	December 31, 2022
Margaret McCaffery	December 31, 2023
Terri McClements	December 31, 2022
Joseph M. Naylor	December 31, 2022
Oyebode Taiwo, MD, MPH	December 31, 2023
Robert Winn, MD	December 31, 2022

## **Michael T. Marquardt, Chair**



Mr. Marquardt has been the chief executive officer of Global Compass Strategies, Inc. since 2009 after serving as CEO of three other companies over the past 25 years. Mr. Marquardt is a global advisor to corporations around the world, working closely with senior leadership teams on business development, strategic planning, and cybersecurity issues. Mr. Marquardt has extensive experience with corporate turn-around situations, crisis management, succession planning, foreign due diligence, and digital transformation at the enterprise level. He served as chair of the former South Atlantic Division Board, received the Society's St. George National Award in 2017, and has served on the American Cancer Society Cancer Action Network's Board of Directors since 2014 and the American Cancer Society Board of Directors since 2018.

## **Brian A. Marlow, CFA, Vice Chair**



Mr. Marlow is the president of KeyBank's South Puget Sound Market in Washington. He is the senior representative and spokesperson for the bank and leads the economic and community development efforts across the organization. He served as a member of the former Great West Division Board and the former National Assembly and has been involved with a number of enterprise-wide committees. He brings a passion for and in-depth knowledge of the Relay For Life program. Mr. Marlow was awarded the St. George National Award in 2014 and has served on the American Cancer Society Board of Directors since 2016.

## **Mark A. Goldberg, MD, Board Scientific Officer**



Dr. Goldberg is a medical oncologist and hematologist on the faculty of Brigham & Women's Hospital and Harvard Medical School, a veteran biotech executive, and long-time American Cancer Society and ACS Cancer Action Network volunteer. Dr. Goldberg currently serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Walden Biosciences, Avacta Group PLC, and Blueprint Medicines. Dr. Goldberg previously served on the executive management team of Synageva Biopharma from 2011-2014. Before that, he served in various management capacities of increasing responsibility at Genzyme Corporation from 1996-2011, most recently as senior vice president of clinical development. Dr. Goldberg is the past chair of the Eastern New England Area Board and was a member of the former New England Division Board. He has served on the American Cancer Society Board of Directors since 2019.

## **Katie A. Eccles, Esq., Secretary/Treasurer**



Ms. Eccles is an attorney of counsel at Ray, Quinney & Nebeker. She currently serves as Vice Chair of the Board of Trustees at the University of Utah, Vice Chair of the Nora Eccles Treadwell Foundation, Assistant Secretary of the Emma Eccles Jones Foundation, and as a board member for the Utah Museum of Fine Arts. Ms. Eccles earned her J.D. at Stanford Law School and previously held a clerkship on the 10th Circuit Court of Appeals. In 2015, she received the local ACS Sword of Hope Award in recognition of her years of service as chair of its Hope Lodge Board to fund, design, and construct the Hope Lodge in Salt Lake City. She has served on the American Cancer Society Board of Directors since 2020.

## **John Alfonso, CPA, CGMA, Immediate Past Chair**



Mr. Alfonso is a partner with CohnReznick LLP, a national advisory, assurance, and tax firm, and leads its Not-for-Profit & Education Industry Practice, which serves over 1,700 organizations nationwide. A frequent panelist and lecturer on not-for-profit accounting standards, board governance, risk management, and information technology, he is an insightful voice that keeps boards and management apprised of key industry developments and relevant best practices. Through his work at CohnReznick, Mr. Alfonso serves a constituency that includes community development corporations, educational institutions, faith-based organizations, governmental entities, museums, private foundations, professional and trade associations, and social service agencies. At the national level of the American Cancer Society, Mr. Alfonso has served on several key board committees. For his tremendous contributions to the fight against cancer, he received the American Cancer Society St. George National Award in 2014. Mr. Alfonso has served on the American Cancer Society Board since 2011.

# At-Large Directors 2022

## **Bruce N. Barron**



Mr. Barron is a Founding Partner of Origin Ventures, an early-stage technology focused venture capital firm with offices in Chicago and Salt Lake City. He is a member of the Boards of Directors of the Chicago Baseball Cancer Charities, and the Chicago chapter Board and the International Board of the Israel Cancer Research Fund. He is also a supporter of, and mentor for, the Origin Ventures Academy for Entrepreneurial Learning at the University of Illinois Champaign/Urbana. Mr. Barron served on the GrubHub Board, which went public in 2014, and has also been involved with the management of several start-up medical technology companies, including Applied NeuroSolutions, Inc. Mr. Barron has served on the American Cancer Society Board of Directors since 2018.

## **Monica M. Bertagnolli, MD, FASCO**



Dr. Bertagnolli is the Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology at Harvard Medical School and a member of the Gastrointestinal Cancer and Sarcoma Disease Centers at Dana-Farber/Brigham & Women's Cancer Center, where she collaborates with colleagues in medical oncology, radiation oncology, and pathology to treat cancer patients in a tertiary care setting. She is also the Group Chair of the Alliance for Clinical Trials in Oncology, a nation-wide NCI-funded clinical trials group, and the Chief Executive Officer of Alliance Foundation Trials, LLC, a not-for-profit corporation that conducts international cancer clinical trials. Dr. Bertagnolli graduated from Princeton University and attended medical school at the University of Utah. She trained in surgery at Brigham and Women's Hospital and was a research fellow in tumor immunology at the Dana Farber Cancer Institute (DF/BWCC). Dr. Bertagnolli currently serves on the Board of Directors of the Prevent Cancer Foundation and has served on the American Cancer Society Board of Directors since 2021.

## **Jennifer R. Crozier**



Ms. Crozier works with leaders across sectors to achieve social impact goals aligned with the Sustainable Development Goals. Most recently, she served as President of the IBM International Foundation and Vice President of IBM Corporate Citizenship. Under her leadership, IBM was named one of the top companies in Corporate Social Responsibility. Ms. Crozier developed and led IBM's version of the Peace Corps – sending over 4,500 IBMers on month long service assignments in developing countries. She also developed IBM's Smarter Cities Challenge to support mayors around the world in harnessing data and technology to achieve their civic priorities and oversaw IBM's innovative P-TECH program which has helped over 100,000 students prepare for 21<sup>st</sup> century jobs. Additionally, Ms. Crozier partnered with American Cancer Society and other global health organizations to address health disparities in sub-Saharan Africa. She has served on the American Cancer Society Board of Directors since 2018.



# At-Large Directors 2022

## Asif Dhar, MD, MBA



Dr. Dhar is vice chairman and US Life Sciences and Health Care (LSHC) Industry leader for Deloitte LLP. He leads the overall strategic direction for the life sciences and healthcare practices, including audit, consulting, tax, and advisory services. He is a respected health futurist and sought-after digital disrupter who works with governments, life sciences, and healthcare clients to reinvent wellness and eradicate disease. Dr. Dhar is also Deloitte's lead partner for the Firm's US Food and Drug Administration (FDA) relationship and responsible for all work Deloitte performs with and for the FDA. His perspectives on real world evidence, regulatory sciences, digital health, and innovation are sought by clients around the world. Dr. Dhar begins his service on the American Cancer Society Board of Directors in 2022.

## Wayne A. I. Frederick, MD, MBA, FACS



Dr. Frederick was appointed the seventeenth president of Howard University in 2014. He previously served as provost and chief academic officer. Most recently, the Howard University Board of Trustees selected Dr. Frederick to serve as the distinguished Charles R. Drew Professor of Surgery. Dr. Frederick has advanced Howard University's commitment to student opportunity, academic innovation, public service, and fiscal stability. He has overseen a series of reform efforts, including the expansion of academic offerings, establishing innovative programs to support student success and the modernization of university facilities. Dr. Frederick is the author of numerous peer-reviewed articles, book chapters, abstracts, and editorials and is a widely recognized expert on disparities in healthcare and medical education. His medical research focuses on narrowing racial, ethnic, and gender disparities in cancer-care outcomes, especially pertaining to gastrointestinal cancers. Dr. Frederick begins his service on the American Cancer Society Board of Directors in 2022.

## Kathleen Gallagher, MSN



With more than 25 years of experience in healthcare administration and operations, Ms. Gallagher is a nationally recognized leader in providing financial, strategic, and operational expertise to academic medical centers and teaching hospitals. As the Executive Vice President and Chief Operating Officer of Thomas Jefferson University, she oversees University operations and administration; management of University's Strategic Plan that sets organizational priorities; coordination of corporate services for the University constituents including Human Resources, Facilities and Real Estate, Marketing and Communications, and Budgeting and Finance. Ms. Gallagher also has administrative responsibility for academic affiliations and partnerships, including the Office of International Affairs. She is a member of the Budget Oversight and Capital Management Committees, the Executive Steering Committee and she represents the University in strategic initiatives including mergers and acquisitions, and joint ventures. Ms. Gallagher begins her service on the American Cancer Society Board of Directors in 2022.

# At-Large Directors 2022

## **Carmen E. Guerra, MD, MSCE, FACSP**



Dr. Guerra is the Ruth C. and Raymond G. Perelman associate professor and vice chair of diversity, equity, and inclusion for the department of medicine as well as the associate director of Diversity and Outreach at the Abramson Cancer Center of the University of Pennsylvania. Dr. Guerra specializes in cancer control, especially eliminating the barriers to accessing cancer screening tests in underserved populations. Dr. Guerra is also an attending physician at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center. She has been a volunteer with ACS since 2004 and serves on the Philadelphia Area Board. Dr. Guerra is a past recipient of an American Cancer Society Cancer Control Career Development Award and was awarded the St. George National Award in 2017. She has served on the American Cancer Society Board of Directors since 2016.

## **Laura Hertz**



Ms. Hertz is the co-founder and CEO of Gifts for Good, an innovative, millennial-driven, and socially conscious startup whose mission is to disrupt the world of business gifting. Prior to co-founding Gifts for Good, Ms. Hertz served as the Creative Director of Cultural Outreach and as an Audit Senior Associate at Deloitte. Ms. Hertz studied Business Administration at UC Berkeley's Haas School of Business and earned her Master's in Social Entrepreneurship at the University of Southern California Marshall School of Business. She has served on the American Cancer Society Board of Directors since 2021.

## **Amit Kumar, PhD**



Dr. Kumar is the President and Chief Executive Officer of Anixa Biosciences and sits on the Boards of other public and private biotechnology companies. He is an experienced research scientist, executive, and investor. Over the last 20 years, Dr. Kumar has performed and managed research programs in both cancer diagnostics and therapeutics. He has also built strong relationships with venture capital firms and other investors in the biotechnology space and has a strong understanding and experience in structuring financial and business transactions. Dr. Kumar has served on the American Cancer Society Board of Directors since 2017.



# At-Large Directors 2022

## Othman Laraki, MS, MBA



Mr. Laraki is the co-founder and chief executive officer of Color, a health technology company building public health infrastructures such as scaled and efficient testing to contain the COVID-19 pandemic or using genomics for population health. Previously, Othman co-founded Mixer Labs and developed its GeoAPI platform, a powerful location engine for developers. After the company was acquired by Twitter in 2009, he served as the social media network's vice president of Product and helped expand its user base from 50 to 200 million unique accounts. Before this, Othman spent several years at Google, where he played an integral role developing front-end products, including the Chrome browser. Othman is a long-time investor and advisor to leading companies such as Pinterest, AngelList, Slack, and Instacart, and serves as a board member for ESI Group and Frontier Medicines. Mr. Laraki begins his service on the American Cancer Society Board of Directors in 2022.

## Michelle M. Le Beau, PhD



Dr. Le Beau is the Chief Scientific Officer of the Cancer Prevention and Research Institute of Texas. She is the Arthur and Marian Edelstein Professor Emerita of Medicine, Section of Hematology/Oncology, Director Emerita of the University of Chicago Medicine Comprehensive Cancer Center, an NCI-designated Comprehensive Cancer Center, and Director Emerita of the Cancer Cytogenetics Laboratory at the University of Chicago. She is board-certified in clinical cytogenetics by the ABMGG. Dr. Le Beau is the past-President of the Association of American Cancer Institutes, and a former member of the Board of Directors for AACR, the Executive Committee of the American Society of Hematology, the Board of Directors for the Leukemia and Lymphoma Society, and the National Cancer Policy Forum of the National Academy of Medicine. She is currently a member of the Board of Scientific Advisors of the National Cancer Institute. Dr. Le Beau has served on the American Cancer Society Board of Directors since 2019.

## Connie Lindsey



Ms. Lindsey is executive vice president and head of Corporate Social Responsibility and Global Diversity, Equity, and Inclusion at Northern Trust, Chicago. She is responsible for the design and implementation of the global Corporate Social Responsibility, Community Development and Investments, and Global Diversity, Equity, and Inclusion strategy for Northern Trust and the development of goals, policies, and programs appropriate to the brand and business unit strategies. In addition, Ms. Lindsey provides oversight and leadership to the firm's response to environmental matters as well as social issues, within the marketplace, workplace, and the community. She begins her service on the American Cancer Society Board of Directors in 2022.

# At-Large Directors 2022

## Edison T. Liu, MD



Dr. Liu is the president and CEO of The Jackson Laboratory. Previously, he was the founding executive director of the Genome Institute of Singapore (2001- 2011) and was the president of the Human Genome Organization (HUGO) from 2007-2013. Between 1997 and 2001, he was the scientific director of the National Cancer Institute's Division of Clinical Sciences in Bethesda, Md., where he oversaw the intramural clinical translational science programs. He obtained his B.S. in chemistry and psychology, as well as his M.D., at Stanford University. He served his internship and residency at Washington University's Barnes Hospital in St. Louis, followed by an oncology fellowship at Stanford. Dr. Liu has served on the American Cancer Society Board of Directors since 2021.

## Margaret McCaffery



Ms. McCaffery and her husband Fran, Iowa head men's basketball coach, have been actively involved with the Coaches vs. Cancer program and have raised significant funds to support American Cancer Society efforts, including more than \$2 million since 2010. The American Cancer Society awarded the McCafferys with the Fighting Spirit Award in 2015. Ms. McCaffery has served on the American Cancer Society Board of Directors since 2018.

## Terri McClements



Ms. McClements' 34-year career at PwC has led her down many pathways for delivering value and innovation to PwC clients. Having served in various leadership capacities, overseeing high performing markets, the development of PwC's human capital and talent programs, the firm's COVID-19 Executive PMO, and Partner Candidate Leadership Development Experience, she has brought to bear the firm's leading specialists to serve clients resulting in significant growth and organizational and digital transformation. These experiences have coalesced into bringing this depth and breadth of the firm to PwC's clients. Ms. McClements is currently leading the Diversity, Equity, & Inclusion Consulting practice and the firm's Partner Candidate Leadership Development program which is focused on increasing the diversity of the partner pipeline. She also serves as the Senior relationship partner and lead client Partner to accounts across all sectors. Ms. McClements has served on the American Cancer Society Board of Directors since 2019.

# At-Large Directors 2022

## Joseph M. Naylor



Mr. Naylor recently retired from his position as vice president of Policy, Government, and Public Affairs for Chevron Corporation. He was responsible for U.S. and international government relations, all aspects of communications, and the company's worldwide efforts to protect and enhance its reputation. Mr. Naylor served on the former California Division Board and has served on the American Cancer Society Board of Directors since 2017.

## Oyebode (Bode) Taiwo, MD, MPH



Dr. Taiwo is Vice President and Chief Medical Officer of 3M where he is responsible for the development of 3M's global health strategy, as well as the leadership and management of the Medical organization. He serves on the Board of Directors of Canvas Health and he is a member of the National Committee on Evidence-Based Benefit Design, National Business Group. Dr. Taiwo has served on the American Cancer Society Board of Directors since 2020.

## Robert Winn, MD



Dr. Winn is the Director and Lipman Chair in Oncology of VCU Massey Cancer Center. In addition to directing the activities of Massey's 250-plus research members – researchers and physicians from 39 departments in nine colleges and schools at VCU – he also manages a research laboratory at VCU. His current basic science research focuses on the molecular mechanisms and novel therapeutic approaches for human models of lung cancer. As a pulmonologist, Dr. Winn is committed to community-engaged research centered on eliminating health disparities. He is a principal investigator on several community-based projects funded by the NIH and National Cancer Institute and has received national and international acclaim for his efforts to empower underserved patient populations, improve healthcare delivery, and ensure equal access to cancer care. Dr. Winn holds a B.A. from the University of Notre Dame and an M.D. from the University of Michigan Medical School in Ann Arbor. He completed an internship and residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago and a fellowship in pulmonary and critical care medicine at the University of Colorado Health Sciences Center in Denver. Dr. Winn has served on the American Cancer Society Board of Directors since 2021.